PROCEPT BioRobotics Corporation Common Stock (PRCT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of PROCEPT BioRobotics Corporation Common Stock (PRCT)
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Key Insights
Critical company metrics and information
Share Price
$99.45Market Cap
$5.38 BillionTotal Outstanding Shares
54.11 Million SharesTotal Employees
626Dividend
No dividendIPO Date
September 15, 2021SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.procept-biorobotics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities, Continuing | $172.87 Million |
Net Cash Flow From Investing Activities | $-17.48 Million |
Net Cash Flow From Investing Activities, Continuing | $-17.48 Million |
Net Cash Flow From Operating Activities, Continuing | $-91.76 Million |
Net Cash Flow, Continuing | $63.63 Million |
Net Cash Flow From Financing Activities | $172.87 Million |
Net Cash Flow | $63.63 Million |
Net Cash Flow From Operating Activities | $-91.76 Million |
Income Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Average Shares | $100.75 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-103.71 Million |
Net Income/Loss | $-103.71 Million |
Basic Earnings Per Share | $2.06 |
Basic Average Shares | $100.75 Million |
Gross Profit | $96.64 Million |
Costs And Expenses | $286.22 Million |
Income/Loss From Continuing Operations Before Tax | $176.57 Million |
Revenues | $176.57 Million |
Operating Income/Loss | $-109.64 Million |
Cost Of Revenue | $79.93 Million |
Income/Loss From Continuing Operations After Tax | $-103.71 Million |
Research and Development | $56.68 Million |
Operating Expenses | $206.29 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Selling, General, and Administrative Expenses | $149.61 Million |
Benefits Costs and Expenses | $0.00 |
Diluted Earnings Per Share | $2.06 |
Net Income/Loss Attributable To Parent | $-103.71 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Balance Sheet
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Fixed Assets | $27.68 Million |
Long-term Debt | $51.40 Million |
Liabilities | $122.57 Million |
Inventory | $43.87 Million |
Other Current Assets | $278.03 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Liabilities | $42.84 Million |
Noncurrent Liabilities | $79.73 Million |
Other Non-current Assets | $24.78 Million |
Assets | $374.35 Million |
Equity Attributable To Parent | $251.78 Million |
Liabilities And Equity | $374.35 Million |
Other Non-current Liabilities | $28.32 Million |
Noncurrent Assets | $52.46 Million |
Equity | $251.78 Million |
Accounts Payable | $9.95 Million |
Other Current Liabilities | $32.90 Million |
Current Assets | $321.89 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.